Sentence: Pertuzumab is the most recent agent approved by the US Food and Drug Administration in combination with trastuzumab and docetaxel for the treatment of patients with HER2(+ ) metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease .
Drug combination annotation:
[{'class': 'POS', 'spans': ['Pertuzumab', 'trastuzumab', 'docetaxel'], 'is_context_needed': False}]